Plagiochiline A Inhibits Cytokinetic Abscission and Induces Cell Death

We previously reported on the isolation and biological activities of plagiochiline A (1), a 2,3-secoaromadendrane-type sesquiterpenoid from the Peruvian medicinal plant, Plagiochila disticha. This compound was found to have antiproliferative effects on a variety of solid tumor cell lines, as well as several leukemia cell lines. Other researchers have also noted the cytotoxicity of plagiochiline A (isolated from different plant species), but there are no prior reports regarding the mechanism for this bioactivity. Here, we have evaluated the effects of plagiochiline A on cell cycle progression in DU145 prostate cancer cells. A cell cycle analysis indicated that plagiochiline A caused a significant increase in the percentage of cells in the G(2)/M phase when compared with control cells. When cells were stained and observed by fluorescence microscopy to examine progress through the mitotic phase, we found a significant increase in the proportion of cells with features of late cytokinesis (cells connected by intercellular bridges) in the plagiochiline A-treated samples. These results suggest that plagiochiline A inhibits cell division by preventing completion of cytokinesis, particularly at the final abscission stage. We also determined that plagiochiline A reduces DU145 cell survival in clonogenic assays and that it induces substantial cell death in these cells.U.S. Department of Defense Prostate Cancer Research Program (PCRP) of the Office of the Congressionally Directed Medical Research Medical Research Program (CDMRP) [W81XWH-07-1-0299]Open access journal.This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at [email protected]

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia

Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-R leukemias are uniquely dependent on the epigenetic function of the H3K79 methyltransferase DOT1L, which is misdirected by MLL-FPs activating gene expression, driving transformation and leukemogenesis. Given the functional necessity of these leukemias to maintain adequate methylation potential allowing aberrant activating histone methylation to proceed, driving leukemic gene expression, we investigated perturbation of methionine (Met)/S-adenosylmethionine (SAM) metabolism as a novel therapeutic paradigm for MLL-R leukemia. Disruption of Met/SAM metabolism, by either methionine deprivation or pharmacologic inhibition of downstream metabolism, reduced overall cellular methylation potential, reduced relative cell numbers, and induced apoptosis selectively in established MLL-AF4 cell lines or MLL-AF6-expressing patient blasts but not in BCR-ABL-driven K562 cells. Global histone methylation dynamics were altered, with a profound loss of requisite H3K79 methylation, indicating inhibition of DOT1L function. Relative occupancy of the repressive H3K27me3 modification was increased at the DOT1L promoter in MLL-R cells, and DOT1L mRNA and protein expression was reduced. Finally, pharmacologic inhibition of Met/SAM metabolism significantly prolonged survival in an advanced, clinically relevant patient–derived MLL-R leukemia xenograft model, in combination with cytotoxic induction chemotherapy. Our findings provide support for further investigation into the development of highly specific allosteric inhibitors of enzymatic mediators of Met/SAM metabolism or dietary manipulation of methionine levels. Such inhibitors may lead to enhanced treatment outcomes for MLL-R leukemia, along with cytotoxic chemotherapy or DOT1L inhibitors

Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins.

The identification of novel combinations of effective cancer drugs is required for the successful treatment of cancer patients for a number of reasons. First, many "cancer specific" therapeutics display detrimental patient side-effects and second, there are almost no examples of single agent therapeutics that lead to cures. One strategy to decrease both the effective dose of individual drugs and the potential for therapeutic resistance is to combine drugs that regulate independent pathways that converge on cell death. BCL2-like family members are key proteins that regulate apoptosis. We conducted a screen to identify drugs that could be combined with an inhibitor of anti-apoptotic BCL2-like proteins, ABT-263, to kill human leukemia cells lines. We found that the combination of D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) hydrochloride, an inhibitor of glucosylceramide synthase, potently synergized with ABT-263 in the killing of multiple human leukemia cell lines. Treatment of cells with PDMP and ABT-263 led to dramatic elevation of two pro-apoptotic sphingolipids, namely ceramide and sphingosine. Furthermore, treatment of cells with the sphingosine kinase inhibitor, SKi-II, also dramatically synergized with ABT-263 to kill leukemia cells and similarly increased ceramides and sphingosine. Data suggest that synergism with ABT-263 requires accumulation of ceramides and sphingosine, as AMP-deoxynojirimycin, (an inhibitor of the glycosphingolipid pathway) did not elevate ceramides or sphingosine and importantly did not sensitize cells to ABT-263 treatment. Taken together, our data suggest that combining inhibitors of anti-apoptotic BCL2-like proteins with drugs that alter the balance of bioactive sphingolipids will be a powerful combination for the treatment of human cancers

Treatment of U937 cells with PDMP, but not AMP-DNM causes accumuliation of ceramide and sphingosine and a decrease in glucosylceramide.

<p>(<b>A</b>) U937 cells were treated with ABT-263 (2 µM), PDMP (45 µM) or the combination of both drugs from two hours. Cells were harvested, lipids were extracted and the amounts of ceramide (Cer), hexosyceramine (HexCer) and lactosylceramide (LacCer) were quantitated. (<b>B</b>) U937 cells were treated with ABT-263 (2 µM), PDMP (45 µM) or the combination of both drugs from two hours. Cells were harvested, lipids were extracted and the amounts of sphingosine (Sph) and spingosine-1 phosphate (S1P) were quantitated. (<b>C</b>) U937 cells were treated with ABT-263 (2 µM), AMP-DNM (45 µM) or the combination of both drugs from two hours. Cells were harvested, lipids were extracted and the amounts of ceramide (Cer), hexosyceramine (HexCer) and lactosylceramide (LacCer) were quantitated. (<b>D</b>) U937 cells were treated with ABT-263 (2 µM), AMP-DNM (45 µM) or the combination of both drugs from two hours. Cells were harvested, lipids were extracted and the amounts of sphingosine (Sph) and spingosine-1 phosphate (S1P) were quantitated.</p

Increased ceramide and sphingosine are important for synergy with ABT-263.

<p>(<b>A</b>) Summary of the lipids that are altered following treatment of U937 cells with various inhibitors. (<b>B</b>) IC50 values of ABT-263 for individual human leukemia cell lines. Values were calculated in prism as the result of dose response curves determined by alamar blue assay 48 hours after ABT-263 treatment. (<b>C</b>) Total levels of basal ceramide (Cer) and sphingosine-1-phosphate (S1P) in four different cell lines as determined by HPLC-MS/MS. Data are normalized to the levels of lipids in U937. (<b>D</b>) Model depicting how different inhibitors affect sphingolipid metabolism.</p

Treatment of cells with AMP-deoxynojirimycin does not synergize with ABT-263.

<p>(<b>A</b>) and (<b>C</b>) Dose response curves of U937 cells and K562 were determined by treating the cells with either increasing doses of AMP (350 nM to 45 µM) plus vehicle or increasing doses of AMP (350 nM to 45 µM) and a constant dose of ABT-263 (2 µM or 60 nM, respectively). (<b>B</b>) and (<b>D</b>) Dose response curves of U937 cells and K562 cells were determined by treating the cells with either increasing doses of ABT-263 (8 nM to 18 µM for U937, 2.2 nM to 5 µM for K562) plus vehicle or increasing doses of ABT-263 (8 nM to 18 µM for U937, 2.2 nM to 5 µM for K562) and a constant dose of AMP (45 µM). Inset values are the calculated IC50 from each curve. (<b>E</b>) U937 cells were treated with ABT-263 (2 µM), PDMP (45 µM) or the combination of drugs for 8 hours and western blots for cleaved CASP3 were performed. (<b>F</b>) Cells were treated with either ABT-263 (60 nM), PDMP (45 µM) or the combination of drugs and 24 hours post treatment cells were stained with anti-AnnexinV antibody and 7AAD to determine the number of cells that were undergoing apoptosis or were already dead.</p

Validation of synergy in K562 cells, a line not used in the screen.

<p>(<b>A</b>) Dose response curves of K562 cells were determined by treating the cells with either increasing doses of PDMP (350 nM to 45 µM) plus vehicle or increasing doses of PDMP (350 nM to 45 µM) and a constant dose of ABT-263 (60 nM). Inset values are the calculated IC50 from each curve. (<b>B</b>) Dose response curves of K562 cells were determined by treating the cells with either increasing doses of ABT-263 (2.2 nM to 5 uM) plus vehicle or increasing doses of ABT-263 (2.2 nM to 5 µM) and a constant dose of PDMP (45 µM). Arrows in (A) and (B) represent equivalent doses of the respective drugs (60 nM ABT-263, 45 µM PDMP) and isobologram analysis indicated that the combination of the two drugs was synergistic with CI = <0.1. Inset values are the calculated IC50 from each curve. (<b>C</b>) Cells were treated with ABT-263 (60 nM), PDMP (45 µM) or the combination of drugs for 2, 4, or 8 hours and western blots for cleaved CASP3 were performed. (<b>D</b>) Cells were treated with either ABT-263 (60 nM), PDMP (45 µM) or the combination of drugs and 24 hours post treatment cells were stained with anti-AnnexinV antibody and 7AAD to determine the number of cells that were undergoing apoptosis or were already dead.</p

A screen identifies PDMP as a drug that can synergistically inhibit the growth of human leukemia cells when combined with ABT-263.

<p>(<b>A</b>) Three human leukemia cell lines were screened against the LOPAC1280 compound library with and without the IC30 of ABT-737. A synergy score was calculated for each compound in the library and the scores of each compound are plotted as a component of each cell line. A lower score indicates a higher level of synergy. U937 cells are plotted on the x-axis, RPMI8226 cells are plotted on the y-axis and HL60 cells are plotted on the z-axis. The point on the graph representing PDMP is indicated. (<b>B</b>) Dose response curves of U937 cells were determined by treating the cells with either increasing doses of PDMP (350 nM to 45 µM) plus vehicle or increasing doses of PDMP (350 nM to 45 µM) and a constant dose of ABT-263 (2 µM). Inset values are the calculated IC50 from each curve. (<b>C</b>) Dose response curves of U937 cells were determined by treating the cells with either increasing doses of ABT-263 (8 nM to 18 µM) plus vehicle or increasing doses of ABT-263 (8 nM to 18 µM) and a constant dose of PDMP (45 µM). Arrows in (<b>B</b>) and (<b>C</b>) represent the equivalent doses of the respective drugs (2 µM ABT-263, 45 µM PDMP) and isobologram analysis indicated that the combination of the two drugs was synergistic with CI = <0.1. Inset values are the calculated IC50 from each curve. (<b>D</b>) Cells were treated with ABT-263 (2 µM), PDMP (45 µM) or the combination of drugs for 2, 4, or 8 hours and western blots for cleaved CASP3 were performed. (<b>E</b>) Cells were treated with either ABT-263 (2 µM), PDMP (45 µM) or the combination of drugs and 24 hours post treatment cells were stained with anti-AnnexinV antibody and 7AAD to determine the percent of cells undergoing apoptosis.</p